
Renfit10 mg
Eskayef Bangladesh Ltd.
Finerenone is a nonsteroidal, selective mineralocorticoid receptor antagonist (MRA) with an established and more.
Finerenone is a nonsteroidal, selective mineralocorticoid receptor antagonist (MRA) with an established, guideline-supported indication:
Finerenone is typically used as an add-on to standard-of-care therapy, including a maximally tolerated dose of an ACE inhibitor or ARB, and in patients with type 2 diabetes who are receiving appropriate glycemic control measures. It is not a substitute for these background therapies.
| Step | Guidance |
|---|---|
| Before starting | Measure serum potassium and eGFR. Do not initiate Finerenone if serum potassium is greater than 5.0 mEq/L. |
| Starting dose | 10 mg once daily if eGFR is 25 to less than 60 mL/min/1.73 m²; 20 mg once daily if eGFR is 60 mL/min/1.73 m² or greater. |
| Dose titration | Measure serum potassium 4 weeks after starting or restarting Finerenone or after any dose adjustment. If potassium is within normal range and eGFR has not declined by more than 30% from baseline, increase the dose to the target of 20 mg once daily (if currently on 10 mg). |
| Maintenance | Continue at the maximum tolerated dose (up to 20 mg once daily), monitoring potassium periodically thereafter. |
Administration: Tablets are taken orally, once daily, with or without food, and swallowed whole. For patients unable to swallow tablets whole, the tablet may be crushed and mixed with water or soft foods such as applesauce immediately before administration; do not chew or crush unless preparing it this way.
See Precautions and Warnings for potassium-based dose adjustment and interruption criteria.
The most common and clinically important adverse effect of Finerenone is hyperkalemia. Other adverse effects reported in clinical trials include:
Less common effects may include mild gastrointestinal upset. Patients should promptly report symptoms such as muscle weakness, irregular heartbeat, dizziness, or fainting, which may indicate hyperkalemia or hypotension.
Finerenone is contraindicated in patients with:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.